Loading data
CGTXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 37.19 m USD | 41.68 m USD | 37.2 m USD | 30.32 m USD | 18.57 m USD |
| Operating profit | -47.8 m USD | -53.97 m USD | -50.72 m USD | -43.55 m USD | -28.6 m USD |
| Net income (reported basis) | -23.49 m USD | -33.97 m USD | -25.79 m USD | -21.4 m USD | -11.72 m USD |
| Net income attributable to common shareholders | — | — | — | -21.4 m USD | -16.25 m USD |
| Basic earnings per share | -0.32 USD/share | -0.86 USD/share | -0.86 USD/share | -0.91 USD/share | -3.13 USD/share |
| Diluted earnings per share | -0.32 USD/share | -0.86 USD/share | -0.86 USD/share | -0.91 USD/share | -3.13 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.